A Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison of Valsartan and Amlodipine in the Treatment of Isolated Systolic Hypertension in Elderly Patients: The Val-Syst Study

Clinical Therapeutics

Volumn 25, Issue 11, 2003, Pages 2765-2780

  Malacco, Ettore ^a   Varì, Natale ^b   Capuano, Vincenzo ^c   Spagnuolo, Vitaliano ^d   Borgnino, Carlo ^e   Palatini, Paolo ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b Vibo Valentia Hospital   (Italy)

^c G Fucito Hospital   (Italy)

^d Annunziata Hospital   (Italy)

^e Medical Department   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

Amlodipine; Edema; Hypertension; Side effects; Valsartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; HYDROCHLOROTHIAZIDE; VALSARTAN;

ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERYTHEMA; ESOPHAGUS DISEASE; ESOPHAGUS PAIN; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HEADACHE; HEART ARRHYTHMIA; HEART RATE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; SYSTOLIC HYPERTENSION; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VIRUS INFECTION; VOMITING;

EID: 0347385170     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80332-6     Document Type: Article

References (30)

1. Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J. 1999;138: 205-210.
2. Hozawa A, Ohkubo T, Nagai K, et al. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: The Ohasama study. Arch Intern Med. 2000;160:3301-3306.
3. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials [published correction appears in Lancet. 2001;357:724]. Lancet. 2000;355:865-872.
4. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151-183.
5. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11:483-489.
6. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996;18:797-810.
7. Maillard MP, Wurzner G, Nussberger J, et al. Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clin Pharmacol Ther. 2002; 71:68-76.
8. Palatini P, Malacco E, Di Somma S, et al. Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: A comparative study between valsartan/hydrochlorothiazide combination and amlodipine. Eur J Clin Pharmacol. 2002;57:765-770.
9. Waeber B, Aschwanden R, Sadecky L, Ferber P. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. J Hypertens. 2001;19:2097-2104.
10. Mallion JM, Carretta R, Trenkwalder P, et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl. 2003;(Suppl 1):36-43.
11. Weir MR, Smith DH, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: Relation to salt intake. Am J Hypertens. 2001;14:665-671.
12. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998;12:861-866.
13. Schmidt A, Adam SA, Kolloch R, et al. Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Blood Press. 2001;10:230-237.
14. Palatini P, Malacco E, Fogari R, et al, for the Italian Collaborative Study Group. A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. J Hypertens. 2001;19:1691-1696.
15. Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: A review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs. 2002; 62:1983-2005.
16. Zanchetti A, Omboni S, La Commare P, et al. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol. 2001;38:642-650.
17. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182-1187.
18. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2000:2015-2017; 2358-2360.
19. UK Prospective Diabetes Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [published correction appears in BMJ. 1999;318:29]. BMJ. 1998;317:703-713.
20. Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
21. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957-1963.
22. Girerd X, Hanon O, Babici D, et al. Rational choice for second antihypertensive agent after failure of the first monotherapy: Therapeutic strategy [in French]. Arch Mal Coeur Vaiss. 2002;95:723-726.
23. Amar J, Vaur L, Perret M, et al, for the PRATIK study investigators. Hypertension in high-risk patients: Beware of the underuse of effective combination therapy (results of the PRATIK study). J Hypertens. 2002;20:779-784.
24. Monane M, Bohn RL, Gurwitz JH, et al. Compliance with antihypertensive therapy among elderly Medicaid enrollees: The roles of age, gender, and race. Am J Public Health. 1996;86:1805-1808.
25. Costa FV. Compliance with antihypertensive treatment. Clin Exp Hypertens. 1996;18:463-472.
26. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
27. Wang PS, Bohn RL, Knight E, et al. Noncompliance with antihypertensive medications: The impact of depressive symptoms and psychosocial factors. J Gen Intern Med. 2002;17:504-511.
28. Dusing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy - the role of adverse effects and compliance. Blood Press. 1998;7:313-315.
29. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol. 2002;18:649-656.
30. Gregoire JP, Moisan J, Guibert R, et al. Tolerability of antihypertensive drugs in a community-based setting. Clin Ther. 2001;23:715-726.